Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer
“In truth, I don’t anticipate prescribing patterns changing immediately,” cardiologist Vishal Khetpal writes of the new cholesterol drug Lipfendra.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersAt least 78 AHRQ grants worth $200 million have been affected by "non-award" notices; it's estimated those grants had $109.2 million in funding remaining.
By Chella·2h ago
Why it mattersScience Corporation announced the European launch of its retinal implant for patients with age-related macular degeneration.
By Chella·1h ago
Why it mattersThe administration is shifting some funding to states, but community groups are set to lose out.
By Chella·21h ago
Why it mattersIn this edition of STAT Health Tech: executive departures at Epic Systems, new CEO takes over at Nabla, and more health tech news.
By Chella·21h ago